Clinical Trial Update: Rifaximin to Modify the Disease Course in Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating rifaximin to modify disease course in sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: New York Medical College | Conditions: Sickle Cell Disease, Antibiotics | Phase 2 | Status: UNKNOWN